1	Altered amyloid plasma profile in patients with disabling headaches after SARS-CoV-2
2	infection and vaccination
3	
4	Anne Hege Aamodt ^{1,2} , Thor Ueland ^{3,4,5} , Marion I. Boldingh ¹ , Burcu Bezgal ¹ , Maria Argren ^{1,4} ,
5	Cecilia Adele Dunne ⁴ , Kari Otterdal ³ , Ida Gregersen ³ , Vigdis Bjerkeli ^{3,4} , Annika Elisabet
6	Michelsen ^{3,4} , Andreas Husøy ^{2,6} , Åse Hagen Morsund ⁷ , Kristina Devik ^{1,8} , Anne Christine
7	Poole ⁹ , Kristine Gjendemsjø ¹⁰ , Katrin Schlüter ¹¹ , Sara Maria Mathisen ¹¹ , Mari Aalstad-
8	Johansen ¹² , Thor Skattør ^{1,4,13} , Julie Sønnervik ¹⁴ , Birgitte Boye ^{15,16} , Trine Haug Popperud ¹ ,
9	Einar August Høgestøl ^{1,4} , Hanne Flinstad Harbo ^{1,4} , Fridtjof Lund-Johansen ^{4,17} , Pål
10	Aukrust ^{3,4,18} , Erling Tronvik ^{2,6} , Tuva Børresdatter Dahl ³ , Bente E. Halvorsen ^{3,4,19}
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	 ¹Department of Neurology, Oslo University Hospital, Oslo, Norway ²Department of Neuromedicine and Movement Science, the Norwegian University of Science and Technology, Trondheim, Norway ³Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway ⁴Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway ⁵Thrombosis Research Center (TREC), Division of internal medicine, University Hospital of North Norway, Tromsø, Norway ⁶Department of Neurology of Clinical Neurophysiology, St. Olav Hospital, Trondheim, Norway ⁷Department of Neurology, Molde Hospital, Molde, Norway ⁸Department of Neurology, Namsos Hospital, Molde, Norway ⁹Oslo Headache Centre, Oslo, Norway ¹⁰Sandvika Neuro Centre, Sandvika, Norway
26 27 28	 ¹²Department of Neurology, Innlandet Hospital Trust, Lillehammer, Norway ¹³Department of Radiology, Oslo University Hospital, Oslo, Norway ¹⁴Hodeverket, Sandnes, Norway
29 30 31 32 33	 ¹³Unit Psychosomatic medicine and CL psychiatry, Oslo University Hospital, Oslo, Norway ¹⁶Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway ¹⁷Department of Immunology, Oslo University Hospital, Oslo, Norway. ¹⁸Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway
34 35 36	¹⁹ Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

38 Abstract

39	Background and objectives: New onset persistent headache has been reported following		
40	acute COVID-19 disease and to some degree also after SARS-CoV-2 vaccination. Still, the		
41	mechanisms for these headache types are unclear. The purpose of this study was to assess		
42	levels of amyloid related biomarkers in patients with persistent headache after COVID-19 and		
43	SARS-CoV-2 vaccine.		
44	Methods: In this prospective observational cohort, patients with severe headache as the		
45	dominating symptom after COVID-19 disease (n=29) and SARS-CoV-2 vaccination (n=31),		
46	had neurological assessments with reassessments after 6 months. Plasma levels of amyloid		
47	precursor protein (APP), pregnancy zone protein (PZP), cathepsin L1 (CTSL) and serum		
48	Amyloid A (SAA1) were measured by ELISA in relation to levels in healthy controls (n=16).		
49	Results: We found a strong and persistent upregulation of APP in patients with headache		
50	after COVID-19 as compared to the two other groups. At both inclusion and after 6 months		
51	APP levels were also increased in those with accompanying cognitive symptoms. In contrast,		
52	plasma levels of PZP were elevated in both headache groups as compared to healthy controls		
53	at inclusion and after 6 months follow-up, but with no relation to cognitive symptoms. CTSL		
54	was only elevated in those with COVID-19 associated headache at baseline, whereas SAA1		
55	showed levels comparable in all groups.		
56	Conclusion: Altered plasma levels of soluble markers potentially reflecting changes in		
57	amyloid processing was found in patients with persistent headache after SARS-CoV-2		
58	vaccine and particular in those with persistent headache after COVID-19 disease where we		
59	also found some association with cognitive symptoms.		
60			
61	NCT04576351		
62	NCT05235776		
63			
64	What is already known on this topic		
65	New onset persistent headache occurs in a subset of individuals after COVID-19 and to some		
66	extent after SARS-CoV-2 vaccine. However, the pathophysiological mechanisms are		
67	unknown.		
68			
69	What this study adds		
70	There was high disability with only modest improvement after 6-month follow-up.		

- 71 Altered plasma levels of soluble markers that potentially could reflect changes in amyloid
- 72 processing was found in patients with persistent headache after SARS-CoV-2 vaccine and
- 73 particular in those with persistent headache after COVID-19 disease with association to
- 74 cognitive symptoms.
- 75

76 How this study might affect research, practice or policy

- 77 Our data point to plausible mechanism of amyloid processing and neuroinflammation in
- 78 relation to COVID-19 and SARS-CoV-2 vaccine.

- 80
- 81

82 Introduction

83	During the COVID-19 pandemic, headache emerged as an important health issue, increasing	
84	the burden of headache disorders. ^{1, 2} Both SARS-CoV-2 infection and, although to a lesser	
85	degree, SARS-CoV-2 vaccination, induced headache as a secondary headache disorder as	
86	well as negatively impact already existing primary headache disorder. ^{1, 3} Thus, those with	
87	primary headache disorder experience headache in the acute phase of COVID-19 and after	
88	vaccination more often than other SARS-CoV-2-infected or vaccinated individuals.1	
89	Approximately one in five patients who present headache during the acute phase of COVID-	
90	19, get persistent headache, often with accompanying symptoms including cognitive	
91	symptoms and fatigue. ¹ Also, a subset of individuals with headache attributed to SARS-CoV-	
92	2 vaccinations develop long lasting headaches. ^{1, 3} Furthermore, in patients with primary	
93	headache disorders, SARS-CoV-2 vaccination and in particular an acute SARS-CoV-2	
94	infection worsened their chronic headache burden. ³ The mechanisms for persistent headaches	
95	after SARS-CoV-2 infection or vaccines are, however, unknown. One proposed mechanism is	
96	persistent immune activation and inflammation triggered by SARS-CoV-2 or vaccination. ^{4, 5}	
97	with the trigeminovascular system as a potential target. ¹ Additionally, the inflammatory	
98	responses during acute COVID-19 disease, involving the release of prostaglandins,	
99	interleukin (IL)-6 and other inflammatory cytokines could increase blood-brain barrier	
100	permeability leading to neuroinflammation with accompanying headache. ^{6,7}	
101	Serum Amyloid A (SAA1), an acute phase protein and systemic marker of	
102	inflammation, was early reported as a biomarker of poor prognosis in COVID-19.8 Recently,	
103	amyloid precursor protein (APP), a membrane protein considered to play a main role in	
104	Alzheimer disease pathology, ⁹ was described as a new receptor for SARS-CoV-2 infection	
105	and revealed a previously unknown mechanistic insight into COVID-19 related	
106	neuropathological sequelae. ¹⁰ Moreover, Pregnancy Zone Protein (PZP), originally known as	
107	a broad-spectrum immune-suppressive protein that suppresses T-cell function during	
108	pregnancy to prevent foetal rejection, has also been proposed as a biomarker for various	
109	inflammatory disorders, ^{11, 12} including the prognosis of COVID-19 disease. ¹³ With relevance	
110	to CNS involvement, serum levels of PZP were higher in women with pre-symptomatic	
111	Alzheimer's disease. ¹⁴ Furthermore, Cathepsin L1 (CTSL), a lysosomal cysteine protease that	
112	plays a major role in intracellular protein catabolism, has been demonstrated to enhance	
113	SARS-CoV-2 virus entry, at least in pre-clinical models, ¹⁵ and interestingly, CTSL has also	
114	been suggested to be involved in the degradation of certain amyloid fibrils. ¹⁶ To this end,	
115	however, circulating levels of these biomarkers (i.e., SAA1, APP, PZP, and CTSL) in patients	

116 with persistent headaches after SARS-CoV-2 infection or vaccination, with or without

117 headache during the acute phase of COVID-19 or immediately after vaccination, have not

been reported.

In the present study, with the aim to give novel insight into the pathological

120 mechanisms leading to persistent headache following COVID-19 and SARS-CoV-2

121 vaccination, we compared plasma levels of APP, PZP, CTSL, and SAA-1 in patients with

122 persistent headache after SARS-CoV-2 infection or vaccination compared with levels in

- 123 healthy controls without headaches. The levels of these molecules were also related to the
- 124 presence of accompanying fatigue or cognitive symptoms, and in the COVID-19 group, the
- 125 need for hospitalization during the acute infection.
- 126

127 Methods

128 In this prospective observational cohort study performed at Norwegian neurological

129 departments and led by Oslo University Hospital, Oslo, Norway, clinical characteristics and

130 blood biomarker profiles were assessed in patients with severe headaches for a minimum of

131 six months after COVID-19 or SARS-CoV-2 vaccination and compared to healthy controls.

132 The inclusion period lasted from September 2020 to June 2023.

133

134 Study population and clinical assessments of the participants

135 The subgroup with **persistent headache after COVID-19** (n=29) was recruited from the

136 cohort of 155 individuals aged \geq 18 years with persistent neurological symptoms 6 months

137 after COVID-19 infection in the Norwegian observational multicentre study of nervous

138 system manifestations and sequelae after COVID infection (NNC), a sub study of the

139 ENERGY study led by European Academy of Neurology.¹⁷ The subgroup with **persistent**

140 headache after SARS-CoV-2 vaccine (n=31) were participants in the Norwegian

141 observational multi-centre study CovaxHEAD: New-onset severe headache after COVID-19

142 vaccine (NCT05235776) - a parallel study led by the same team as the NNC study collecting

143 comparable variables.

Inclusion criteria for both subgroups were $age \ge 18$ years and new onset severe headache or severe worsening of pre-existing headache within one week after SARS-CoV-2 infection or vaccination. The degree of headache severity had to be so pronounced that the headaches were daily or almost daily and had resulted in significant disability or sick leave and still were the dominant symptom at 6-month follow-up. Exclusion criteria were shortlasting headaches, no follow-up assessments, or where other diagnoses were considered a

150 better explanation for their symptoms (e.g. infections including COVID-19, head trauma, or

151 somatoform disorders). Participants with COVID-19 disease who reported their headaches

- 152 starting after SARS-CoV-2 vaccination were not included. Thus, none in this COVID-19
- 153 subgroup had SARS-CoV-2 vaccine induced headache.
- For both headache groups, an inclusion criterion was available plasma samples that could be used in biomarker analyses. The clinical data, including the headache diagnoses, were reviewed by a senior neurologist with headache expertise (AHA).
- 157 The **control group** consisted of healthy individuals (n=16) based on disease history
- 158 without migraine or any other disabling headache disorders and who had never experienced
- 159 neurological symptoms after SARS-CoV-2 vaccine or COVID-19. Additional inclusion
- 160 criteria in the control group were no immunological disorders or use of immunosuppressive

161 drugs. The healthy controls, consisting of 8 men and 8 women, mean age 40.6 years (SD

162 11.2), were recruited from local advertisements at Oslo University Hospital.

163 Blood sampling protocol

- 164 Peripheral venous blood was drawn into pyrogen-free blood collection tubes with
- 165 ethylenediamine tetraacetic acid (EDTA) as an anticoagulant, immediately immersed in
- 166 melting ice and centrifuged at 4°C $2500 \times g$ for 20 minutes within 60 minutes to obtain
- 167 platelet-poor plasma. The plasma samples were stored in multiple aliquots and thawed only
- 168 once.

169 **Biomarker assessments**

- 170 Plasma markers were assessed in all three groups patients with persistent headache after
- 171 COVID-19 infection (n=29), patients with persistent headache after the COVID-19 vaccine
- 172 (n=31), and healthy controls (n=16). The participants had blood samples drawn when they
- 173 were included in the study. Additionally, 6-month follow-up blood sampling was done in the
- 174 headache groups. Plasma levels of APP (Cat# DY850), PZP (Cat# DY8280-05), CTSL (Cat#
- 175 DY952), and SAA1 (Cat# DY3019-05) were measured by enzyme-linked immunosorbent
- assay (ELISA) using commercially available antibodies (R&D Systems, Minneapolis, MN) in
- 177 a 384-format using a combination of a SELMA pipetting robot (Analytik Jena AG, Jena,
- 178 Germany) and a BioTek dispenser/washer (BioTek Instruments, Winooski, VT). Absorption
- 179 was read at 450 nm by using an EIA plate reader (BioTek Instruments) with wavelength
- 180 correction set to 540 nm. Intra- and inter-assay coefficients of variation for these analyses
- 181 were all <10%.
- 182

183 **Ethics approval**

184 This study was conducted in accordance with the Helsinki Declaration as revised in 2013.

185 Ethical approval for this study was obtained from The Norwegian South-Eastern Ethical

186 Committee (152727 NNC, 351097 CovaxHEAD). Written informed consent was obtained

- 187 from all subjects before inclusion into the study.
- 188

189 Statistics

190 Statistical Package for Social Science (IBM SPSS Inc., version 29 for Windows) was used for

191 statistical analysis. Differences in patient characteristics were tested using the Chi-square test

192 or Fisher's exact test for categorical variables, and the Mann-Whitney U test for continuous

193 variables. Prevalence of characteristics (frequency and percentages) were calculated for each

194 group. A two-sided p-value of <0.05 was deemed statistically significant.

195

196 Results

197 Characteristics and headache phenotypes in the study group

198 Demographics such as age, gender and co-morbidities are shown in Table 1. There was equal

age and sex distribution in both headache groups (i.e., persistent headache following COVID-

200 19 or SARS-CoV-2 vaccination, respectively) with 3 out of 4 participants being female.

201 Comorbidity of frequent diseases, such as pre-existing migraine, allergies, anxiety, and

202 depression were common in both groups. Few had cardiovascular or metabolic disorders.

203 One-third of the patients with persistent headache after COVID-19 infection was hospitalised

204 in the acute phase of the infection. In the group with a persistent headache after SARS-CoV-2

205 vaccine 17 (54.8%) reported previous COVID-19 at baseline, but importantly, without any

206 persistent headache after the infection (Table 1). There was a high disability among the

- 207 participants of both headache groups. More than two thirds of the participants with post
- 208 COVID-19 and more than half the participants with headache post SARS-CoV-2 vaccination

209 were on sick-leave due to the current symptoms at inclusion with only a modest reduction in

the percentages on sick-leave at 6-month follow-up (72.4 % to 65.5 % and 58.1 % to 45.2 %,

211 post COVID-19 and SARS-CoV-2 vaccination, respectively; Table 1). Cognitive symptoms

and fatigue were common, but not dominating (see Methods), in both headache groups (Table

213

1).

214

215 Table 1. Demographic and clinical characteristics at inclusion

Characteristics	Headaches	Headaches	P value
	after COVID-	SARS-CoV-2	
	19	vaccine	
	n = 29	n = 31	
Mean age at inclusion, (SD)	43.5 (11.2)	43.8 (12.4)	0.836
Female, n (%)	22 (75.9)	24 (77.4)	0.862
Education			
Secondary school n (%)	2 (6.8)	7 (22.6)	0.193
College/university \leq 4 years, n (%)	14 (48.3)	12 (38.7)	
College/university > 4 years, n (%)	13 (44.8)	12 (38.7)	
Hospitalisation during COVID-19, n	9 (31 0)	3 (97)	
(%)) (51.0)	5 (5.7)	
Smoking, n (%)	1 (4.4)	2 (6.5)	0.610
Pre-existing migraine, n (%)	11 (31.0)	12 (38.7)	0.871
Comorbidities			
Allergy, n (%)	16 (55.1)	13 (41.9)	0.240
Asthma, n (%)	2 (6.9)	6 (19.4)	0.150
Depression, n (%)	8 (27.6)	10 (32.3)	0.759
Anxiety, n (%)	7 (24.1)	13 (41.9)	0.170
Diabetes, n (%)	0	1 (3.3)	0.330
Cardiovascular disease, n (%)	0	1 (3.3)	0.330
Stroke, n (%)	0	0	
Associated symptoms			
Fatigue, n (%)	22 (75.9)	20 (64.5)	0.204
Subjective cognitive symptoms, n (%)	22 (75.9)	17 (54.8)	0.119
Sick leave at first visit, n (%)	21 (72.4)	18 (58.1)	0.244
Sick leave at 6-month follow-up, n (%)	19 (65.5)	14 (45.2)	0.207

216

217 Biomarkers in relation to post-COVID-19 headache and headache following SARS-

218 **CoV-2 vaccination**

219 At both inclusion and after 6 months, we found a strong and persistent upregulation of APP in 220 patients with headache after COVID-19 as compared to individuals with vaccine induced 221 headache and healthy controls (Figure 1A). There was also upregulation of CTSL in patients 222 with headache after COVID-19 as compared to individuals with vaccine induced headache 223 and healthy controls at inclusion, but these differences were not seen at 6 months follow-up 224 (Figure 1B). In contrast, plasma levels of PZP were elevated in both headache groups as 225 compared to healthy controls at inclusion and after 6 months follow-up (Figure 1C). As for 226 SAA1, being a classical acute phase protein reflecting inflammation, there were no 227 differences between the two headache groups and healthy controls either at baseline or during 228 follow-up (Figure 1D). Finally, whereas post-COVID-19 symptoms have been related to disease severity during the acute phase,¹⁸ we found no differences in the actual biomarkers 229 230 between those who were hospitalized and those who were not hospitalized during the acute 231 phase of COVID-19 (data not shown). 232 233 Biomarker levels in relation to associated fatigue and cognitive symptoms 234 There was a significant upregulation of APP among participants with accompanying cognitive 235 symptoms in the group with persistent headache after COVID-19, but this pattern was not 236 seen in those with headache after SARS-CoV-2 vaccination (Figure 2). Although those with 237 fatigue also had higher levels of APP compared with those without, the difference did not 238 reach statistical significance (Figure 2). As for PZP, CTSL, there were no differences between

- those with or without associated cognitive symptoms or fatigue, neither in the COVID-19 nor
- 240 the SARS-CoV-2 group (data not shown).

241

242 Discussion

243 Persistent headache has been reported following acute COVID-19 disease and to some degree

also after SARS-CoV-2 vaccination.^{1,3} In the present study, we report higher plasma levels of

- APP in patients with persistent headache after COVID-19 disease, but not in patients with
- 246 persistent headache following SARS-CoV-2 vaccination, compared to healthy controls.
- 247 Remarkably, elevated APP persisted at 6 months follow-up and was associated with
- 248 accompanying cognitive symptoms. Notably, plasma levels of PZP were higher in both
- 249 headache groups as compared to controls with a similar pattern after 6 months follow-up. This
- 250 is to the best of our knowledge, the first report that relates proteins involved in amyloid
- formation in persistent headache following COVID-19 disease, and for PZP, also in
- 252 individuals with persistent headache after SARS-CoV-2 vaccination.

253 As depicted in Figure 3, our data point to plausible mechanism of serum APP and PZP 254 proteins in relation to COVID-19 and SARS-CoV-2 vaccine induced headache. In brief, APP 255 is produced by neurons and proteolysis by different secretases may produce a soluble (s) 256 fragment, sAPP, and release of the neurotoxic Aβ peptide. SARS-CoV-2 infection may increase APP expression via the ACE2 receptor^{19, 20} and APP promotes cellular entry of the 257 virus enhancing Aβ-associated pathology.¹⁰ The Aβ peptide may accumulate and form 258 amyloid plaques²¹ leading to activation of astrocytes and microglia and promote 259 neuroinflammation by different mechanisms²² with potential effect on headache symptoms.²³ 260 261 Increased levels of APP is reported as marker for preclinical Alzheimer disease, 262 however, this protein biological function is beyond that of amyloid formation²⁴ and elevated levels has been found in various metabolic and cardiovascular disorders.²⁵ In the present 263 264 study, however, few or none had such clinically verified co-morbidities. However, we found 265 significant upregulation of APP among participants with accompanying cognitive symptoms 266 in the group with persistent headache after COVID-19 compared to those without cognitive 267 symptoms. Moreover, network analyses of SARS-CoV-2 infection in brain microvascular endothelial cells suggested increased expression of APP.¹⁹ In a previous study of patients with 268 269 COVID-19 associated neurological syndromes, signs of impaired amyloid processing was 270 found with significantly reduced soluble amyloid precursor protein in CSF from patients 271 compared to controls.²⁶ However, this study was dominated of patients with severe 272 neurological diseases such as Guillain Barre syndrome and encephalopathy and only one patient was described with central pain syndrome.²⁶ Furthermore, cognitive symptoms were 273 274 not reported. At present, however, the reason for and the clinical consequences of the raised 275 APP in patients with persistent headache following COVID-19 disease is elusive and follow-276 up studies are clearly needed. 277 In contrast to APP, plasma levels of PZP were persistently elevated in both headache 278 groups, i.e., prolonged headache following both COVID-19 and SARS-CoV-2 vaccination. 279 The reason for this pattern is so far unclear. PZP is known to promote a beneficial 280 immunosuppression during pregnancy to avoid rejection of the foetus. More recently, increased PZP levels has been found during airway infections¹² and have been suggested as a 281 marker of certain cancers.²⁷ Moreover, previous studies with mouse models have indicated 282 283 that APP can increase the entry of the SARS-Cov-2 virus into cells whereas PZP has been described to inhibit amyloid aggregation.²⁸ Since APP was lower in the vaccine group than 284 285 the COVID-19 group, one intriguing hypothesis is that PZP were able to inhibit amyloid 286 aggregation at a higher degree in the vaccine group than in the COVID-19 group. However,

PZP has also been reported to stabilize misfolding proteins like amyloid β protein, and the role of PZP in amyloid formation is still not clear.²⁸

- 289 The strengths of this study were the comprehensive examinations of the participants
- 290 done by headache specialists with precise phenotyping of the headache syndromes and the
- 291 strong multidisciplinary collaboration. The major limitations were the lack of CSF samples in
- both headache groups. Moreover, we lack parallel samples from CSF and measurements of
- the actual protein in individuals that have undergone COVID-19 and SARS-CoV-2
- vaccination without the development of persistent headache.
- In summary, altered plasma levels of soluble markers that potentially could reflect
- 296 changes in amyloid processing was found in patients with persistent headache after SARS-
- 297 CoV-2 vaccine and particular in those with persistent headache after COVID-19 disease with
- association to cognitive symptoms. Future and larger studies that also include CSF samples
- are needed to further elaborate the clinical consequences of these findings.
- 300
- 301 Acknowledgement: We thank Marcus Boateng for registering data and Katrine Persgård
- 302 Lund and Azita Rashidi for the processing of blood biomarkers.

303 References

304 1. Caronna E, van den Hoek TC, Bolay H, et al. Headache attributed to SARS-CoV-2 305 infection, vaccination and the impact on primary headache disorders of the COVID-19 306 pandemic: A comprehensive review. Cephalalgia 2023;43:3331024221131337. 307 2. Shen Q, Joyce EE, Ebrahimi OV, et al. COVID-19 illness severity and 2-year 308 prevalence of physical symptoms: an observational study in Iceland, Sweden, Norway and 309 Denmark. Lancet Reg Health Eur 2023;35:100756. 310 Atalar AC, Acarli ANO, Baykan B, et al. COVID-19 vaccination-related headache 3. 311 showed two different clusters in the long-term course: a prospective multicenter follow-up 312 study (COVA-Head Study). J Headache Pain 2023;24:132. 313 4. Files JK, Sarkar S, Fram TR, et al. Duration of post-COVID-19 symptoms is 314 associated with sustained SARS-CoV-2-specific immune responses. JCI Insight 2021;6. 315 5. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-316 CoV-2. Nature 2021;591:639-644. 317 6. Garces KN, Cocores AN, Goadsby PJ, Monteith TS. Headache After Vaccination: An 318 Update on Recent Clinical Trials and Real-World Reporting. Curr Pain Headache Rep 319 2022;26:895-918. 320 Hervé CL, B.; Del Giudice, G.; Didierlaurent, AM.; Tavares Da Silva, F. . The how's 7. 321 and what's of vaccine reactogenicity. NPJ Vaccines 2019;4. 322 Li HX, X.; Ren, H.; Xu, L.; Zhao, L.; Chen, X.; Long, H.; Wang, Q.; Wua, Q. Serum 8. 323 Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis. J Infect 324 2020;80:646-655. 325 9. Orobets KS, Karamyshev AL. Amyloid Precursor Protein and Alzheimer's Disease. Int 326 J Mol Sci 2023;24. 327 Chen J, Chen J, Lei Z, et al. Amyloid precursor protein facilitates SARS-CoV-2 virus 10. 328 entry into cells and enhances amyloid-beta-associated pathology in APP/PS1 mouse model of 329 Alzheimer's disease. Transl Psychiatry 2023;13:396. 330 11. Shao J, Jin Y, Shao C, Fan H, Wang X, Yang G. Serum exosomal pregnancy zone 331 protein as a promising biomarker in inflammatory bowel disease. Cell Mol Biol Lett 332 2021;26:36. 333 12. Finch S, Shoemark A, Dicker AJ, et al. Pregnancy Zone Protein Is Associated with 334 Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in 335 Bronchiectasis. Am J Respir Crit Care Med 2019;200:992-1001. Villar M, Urra JM, Rodriguez-Del-Rio FJ, et al. Characterization by Quantitative 336 13. 337 Serum Proteomics of Immune-Related Prognostic Biomarkers for COVID-19 338 Symptomatology. Front Immunol 2021;12:730710. 339 14. Ijsselstijn L, Dekker LJ, Stingl C, et al. Serum levels of pregnancy zone protein are 340 elevated in presymptomatic Alzheimer's disease. J Proteome Res 2011;10:4902-4910. 341 15. Zhao MM, Yang WL, Yang FY, et al. Cathepsin L plays a key role in SARS-CoV-2 342 infection in humans and humanized mice and is a promising target for new drug development. 343 Signal Transduct Target Ther 2021;6:134. 344 Wang H, Sang N, Zhang C, Raghupathi R, Tanzi RE, Saunders A. Cathepsin L 16. 345 Mediates the Degradation of Novel APP C-Terminal Fragments. Biochemistry 2015;54:2806-346 2816. 347 Beghi E, Moro E, Davidescu EI, et al. Comparative features and outcomes of major 17. 348 neurological complications of COVID-19. Eur J Neurol 2023;30:413-433. 349 18. Headache Classification Committee of the International Headache Society (IHS) The 350 International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211.

351 19. Camacho RC, Alabed S, Zhou H, Chang SL. Network Meta-analysis on the Changes 352 of Amyloid Precursor Protein Expression Following SARS-CoV-2 Infection. J Neuroimmune 353 Pharmacol 2021;16:756-769. 354 Caradonna A, Patel T, Toleska M, Alabed S, Chang SL. Meta-Analysis of APP 20. 355 Expression Modulated by SARS-CoV-2 Infection via the ACE2 Receptor. Int J Mol Sci 356 2022;23. 357 21. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. 358 Annu Rev Neurosci 2011;34:185-204. 359 Di Benedetto G, Burgaletto C, Bellanca CM, Munafo A, Bernardini R, Cantarella G. 22. 360 Role of Microglia and Astrocytes in Alzheimer's Disease: From Neuroinflammation to Ca(2+) 361 Homeostasis Dysregulation. Cells 2022;11. 362 Kursun O, Yemisci M, van den Maagdenberg A, Karatas H. Migraine and 23. 363 neuroinflammation: the inflammasome perspective. J Headache Pain 2021;22:55. 364 24. Zheng H, Koo EH. The amyloid precursor protein: beyond amyloid. Mol 365 Neurodegener 2006;1:5. 366 25. Guo Y, Wang Q, Chen S, Xu C. Functions of amyloid precursor protein in metabolic 367 diseases. Metabolism 2021;115:154454. 368 26. Ziff OJ, Ashton NJ, Mehta PR, et al. Amyloid processing in COVID-19-associated

- neurological syndromes. J Neurochem 2022;161:146-157.
 27. Huang J, Xu Y, Chen Y, et al. Revisiting the role of pregnancy zone protein (PZP) as a
- 371 cancer biomarker in the immunotherapy era. J Transl Med 2024;22:500.
- 372 28. Cater JH, Kumita JR, Zeineddine Abdallah R, et al. Human pregnancy zone protein
- 373 stabilizes misfolded proteins including preeclampsia- and Alzheimer's-associated amyloid
- beta peptide. Proc Natl Acad Sci U S A 2019;116:6101-6110.

376 Figure legends

- 377 Figure 1. Plasma levels of A. Amyloid Precursor Protein (APP), B. Cathepsin L., C.
- 378 Pregnancy Zone Protein (PZP) and **D**. Serum Amyloid A (SAA1) in healthy controls (HC)
- 379 (n=16), participants with persistent headache after SarsCoV-2 vaccine (COvax) (n=31) and
- 380 participants with persistent headache after COVID-19 (C19) (n=29).
- 381
- **Figure 2.** Plasma levels of Amyloid Precursor Protein (AAP) in relation to cognitive
- 383 symptoms and fatigue in those with persistent headache after SARS-CoV-2 vaccine (COvax)
- 384 or COVID-19 (C19).
- 385
- **Figure 3.** Possible mechanisms of soluble Amyloid Precursor Protein (sAPP) and Pregnancy
- 387 Zone Protein (PZP) in relation to COVID-19 and SARS-CoV-2 vaccination associated
- 388 headache. The authors wish to acknowledge SERVIER Medical Art (www.servier.fr) for use
- 389 of their medical art kits when making the illustration in the article.

- 390 **Study funding:** Supported by Oslo University Hospital and the Southern and Eastern Norway
- 391 Regional Health Authority (2021051).
- 392 Acknowledgement: We thank Marcus Boateng for registering data and Katrine Persgård
- 393 Lund and Azita Rashidi with the sampling of blood biomarkers.
- 394 Statistical Analysis: Thor Ueland and Anne Hege Aamodt
- 395 Disclosure
- 396 **Conflicts of interest:** The authors report no disclosures relevant to this study.
- 397 A.H. Aamodt has received honoraria for advice or lecturing from Pfizer Allergan, Teva,
- 398 Novartis, Roche, Lundbeck and Teva and research grant from Boehringer Ingelheim.
- 399 Anne Christine Poole: lecturing, advisory boards and/or clinical studies: Abbvie, Lundbeck,
- 400 Pfizer, Novartis, Teva, Eli Lilly
- 401

Co-investigators	Affiliations	
Øyvind Torkildsen	Neuro-SysMed, Department of Neurology,	
	Haukeland University Hospital, Bergen,	
	Norway; Department of Clinical Medicine,	
	University of Bergen, Bergen, Norway	
Vojetch Novotny	Department of Neurology, Haukeland	
	University Hospital, Bergen, Norway	
Heidi Øyen Flemmen	Department of Neurology, Telemark	
	Hospital Trust, Skien, Norway	
Hilde Karen Ofte	Department of Neurology,	
	Nordlandssykehuset, Bodø, Norway	
Christian Samsonsen	Department of Neurology of Clinical	
	Neurophysiology, St. Olav Hospital,	
	Trondheim, Norway	
Barbara Ratajczak-Tretel	Department of Neurology, Østfold Hospital	
	Trust, Sarpsborg, Norway	
Anette Huuse Farmen	Department of Neurology, Innlandet	
	Hospital Trust, Lillehammer, Norway	
Per Selnes	Department of Neurology, Akershus	
	University Hospital, Nordbyhagen, Norway	
	and Institute of Clinical Medicine, Faculty	
	of Medicine, University of Oslo, Oslo,	
	Norway	
Stein Andersson	Department of Psychology, University of	
	Oslo, Oslo, Norway	
Erlend Bøen	Unit for Psychosomatics and C-L psychiatry	
	for adults, Oslo University Hospital, Oslo,	
	Norway	

	Siv Elin Pignatiello	Unit for Psychosomatics and C-L psychiatry
		for adults, Oslo University Hospital, Oslo,
		Norway and Institute of Clinical Medicine,
		Faculty of Medicine, University of Oslo,
		Oslo, Norway
402		





